Prostate Cancer Clinical Trial

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

Summary

RATIONALE: Valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether valproic acid is more effective than observation in treating patients with prostate cancer.

PURPOSE: This randomized phase II trial is studying how well valproic acid works in treating patients with progressive, non-metastatic prostate cancer.

View Full Description

Full Description

OBJECTIVES:

Primary

Assess whether treatment with valproic acid (a type I histone deacetylase inhibitor) can alter the kinetics of prostate-specific antigen (PSA) progression in patients with non-metastatic prostate cancer and biochemical progression.

Secondary

Determine the duration of PSA response.
Assess the percentage of patients who achieve a complete response.
Assess the percentage of patients who achieve a partial response.
Assess the quality of life of these patients.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 arms.

Arm I (observation): Patients undergo observation according to standard of care.
Arm II (valproic acid): Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity.

Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed prostate cancer

Asymptomatic, non-metastatic disease

Biochemical progression after definitive local therapy (radical prostatectomy)

Most recent prostate-specific antigen (PSA) level ≥ 1.0 ng/mL AND rising over the prior value
No clinical or radiological evidence of local progression

PSA doubling time (DT) < 10 months after local therapy (in patients who have not received prior hormone therapy)

At least three PSA values (each at least 4 weeks apart) are required to calculate the PSA-DT
No clinical or radiological evidence of metastatic disease, including bone metastasis

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
Life expectancy > 3 months
Total bilirubin normal
AST/ALT < 2.5 times upper limit of normal
Creatinine ≤ 2.5 mg/dL
Platelet count > 125,000/mm^3
PT and aPTT ≤ 1.3 times above the standard reference
Albumin ≥ 3.5 g/dL
Geographically accessible and willing to participate in all stages of study treatment
No active second malignancy
No known HIV positivity
No active, uncontrolled infection (e.g., hepatitis A, B, or C infection)
No history of allergic reactions attributed to compounds of similar chemical or biological composition to valproic acid
No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal study treatment and follow-up
No history of hepatic disease or significant hepatic dysfunction
No history of pancreatitis
No history of seizure disorder or clinically treated bipolar disorder

PRIOR CONCURRENT THERAPY:

More than 6 months since prior hormone therapy
No prior valproic acid
At least 2 weeks since prior drugs specifically known to interact with valproic acid including, but are not limited to, aspirin, felbamate, rifampin, amitriptyline/nortriptyline, carbamazepine, clonazepam, diazepam, ethosuximide, lamotrigine, phenobarbital, primidone, phenytoin, tolbutamide, warfarin, or zidovudine
No concurrent systemic chemotherapy for prostate cancer
No other concurrent investigational drugs

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

15

Study ID:

NCT00670046

Recruitment Status:

Terminated

Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore Maryland, 21231, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

15

Study ID:

NCT00670046

Recruitment Status:

Terminated

Sponsor:


Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider